Gilead Sciences, Inc. GILD shares are volatile in Tuesday's post-market session after the company beat Wall Street revenue and earnings estimates handily.
Perhaps more importantly to some investors, Gilead reported that sales for its Hep C drugs, Harvoni and Sovaldi, totaled $4.89 billion for the quarter, above the Wall Street consensus of $4.45 billion.
Gilead said its projects total product sales between $30 billion and $31 billion this year, equal to what analysts were expecting, Reuters reports.
Separately, social media chatter is circulating that said Gilead Harvoni U.S. sales ($1.707 billion) missed expectations by over 20 percent, while international sales ($1.638 billion) beat by 80 percent.
These figures have not been verified by an analyst; Gilead has not yet returned a request for comment on this issue.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.